Solid lipid nanoparticle

About: Solid lipid nanoparticle is a research topic. Over the lifetime, 3175 publications have been published within this topic receiving 127912 citations. The topic is also known as: LNP & SLN.

Iron-oxide embedded solid lipid nanoparticles for magnetically controlled heating and drug delivery

Abstract: This paper presents the development of magnetic lipid nanoparticles that could serve as controlled delivery vehicles for releasing encapsulated drugs in a desired manner. The nanoparticles are composed of multiple drugs in lipid matrices, which are solid at body temperature and melt around 45 degrees C to 55 degrees C. In addition, super-paramagnetic gamma-Fe2O3 particles with sizes ranging from 5 to 25 nm are surface modified and dispersed uniformly in the lipid nanoparticles. In the prototype demonstration, lipid nanoparticles with average sizes between 100 and 180 nm were fabricated by high-pressure homogenization at elevated temperatures. When exposed to an alternating magnetic field of 60 kA/m at 25 kHz, a solution containing 2 g/L encapsulated gamma-Fe2O3 particles showed a temperature increase from 37 degrees C to 50 degrees C in 20 min. Meanwhile, the dissipated heat melted the surrounding lipid matrices and resulted in an accelerated release of the encapsulated drugs. Within 20 min, approximately 35% of the encapsulated drug molecules were released from the lipid nanoparticles through diffusion. As such, the presented lipid nanoparticles enable a new scheme that combines magnetic control of heating and drug delivery, which could greatly enhance the performance of encapsulated drugs.

Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction

Abstract: Objective: The aim of this study was to prepare sildenafil citrate as solid lipid nanoparticles (SLNs), in order to find an innovative way for alleviating the disadvantages associated with commercially available sildenafil citrate tablets. These limitations include poor solubility and extensive first-pass metabolism, resulting in low (40%) bioavailability and short elimination half-life (4 h).Methods: SLNs were prepared by hot homogenization followed by ultrasonication. Solubility of sildenafil citrate in different solid lipids was measured, effect of process variables as surfactant type and concentration, homogenization time, ultrasonication time and charge-inducing agent on the particle size, zeta potential and encapsulation efficiency were also determined. Furthermore, in vitro drug release, stability and in vivo pharmacokinetics were studied in rabbitsResults: The best SLN formula consisted of 2% precirol ATO5, 0.5% phosphatidylcholine, 2.5% gelucire 44/14, 0.125% stearylamine, had an average particle...

Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.

Abstract: Purpose: Zaleplon (ZL) is a hypnotic drug prescribed for the management of insomnia and convulsions. The oral bioavailability of ZL was low (∼30%) owing to poor water solubility and hepatic first-pass metabolism. The cornerstone of this investigation is to develop and optimize solid lipid nanoparticles (SLNs) of ZL with the aid of Box–Behnken design (BBD) to improve the oral bioavailability.Methods: A design space with three formulation variables at three levels were evaluated in BBD. Amount of lipid (A1), amount of surfactant (A2) and concentration of co-surfactant (%) (A3) were selected as independent variables, whereas, particle size (B1), entrapment efficiency (B2) and zeta potential (ZP, B3) as responses. ZL-SLNs were prepared by hot homogenization with ultrasonication method and evaluated for responses to obtain optimized formulation. Morphology of nanoparticles was observed under SEM. DSC and XRD studies were examined to understand the native crystalline behavior of drug in SLN formulations...

Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system.

Abstract: In order to improve drug entrapment efficiency and loading capacity, nanostructured lipid carriers consisting of solid lipid and liquid lipid as a new type of colloidal drug delivery system were prepared. The dispersions of oridonin-loaded solid lipid nanoparticles and nanostructured lipid carriers were successfully prepared by the emulsion-evaporation and low temperature-solidification technique using monostearin as the solid lipid, caprylic/capric triglycerides as the liquid lipid and oridonin as the model drug. Their physicochemical properties of oridonin-loaded nanostructured lipid carriers and release behaviours were investigated and compared with those of solid lipid nanoparticles. As a result, the mean particle size was approximately 200 nm with narrow polydispersity index lower than 0.4 for all developed formulations. Zeta potential values were in the range -35 mV approximately -50 mV, providing good physical stability of all formulations. The differential scanning calorimetry and X-ray diffraction analysis results demonstrated lipid nanoparticles exhibited crystal order disturbance and thus left more space to accommodate drug molecules. The improved drug entrapment efficiency and loading capacity were observed for nanostructured lipid carriers and they enhanced with increasing the caprylic/capric triglycerides content. In vitro drug release experiments exhibited biphasic drug release patterns with burst release initially and prolonged release afterwards. These results indicated that nanostructured lipid carriers could potentially be exploited as a delivery system with improved drug entrapment efficiency and controlled drug release.